INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Becton, Dickinson And Company (BDX) Investors

BDX) securities between November 5, 2019 and February 5, 2020, inclusive (the "Class Period"). Becton investors have until April 27, 2020 to file a lead plaintiff motion.” data-reactid=”11″>Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Becton, Dickinson and Company (“Becton” or the “Company”) (NYSE: BDX) securities between November 5, 2019 and February 5, 2020, inclusive (the “Class Period”). Becton investors have until April 27, 2020 to file a lead plaintiff motion.

howardsmith@howardsmithlaw.com.

On February 6, 2020, Becton lowered its fiscal 2020 guidance, announcing that it expected revenue to increase by only 1.5 to 2.5 percent, “to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.” According to the Company, the software remediation plan for the Alaris system “will require additional regulatory filings,” and existing customers would have “access to the Alaris System under medical necessity.” Becton further disclosed that it had recorded a $59 million charge in connection with a voluntary recall of certain Alaris pumps.

More:  Becton, Dickinson's Debt Overview

On this news, Becton’s share price fell $33.74, or nearly 12%, to close at $252.25 per share on February 6, 2020, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that certain of Becton’s Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) that, as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to “make enhancements;” (3) that the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) that, as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

www.howardsmithlaw.com.” data-reactid=”16″>If you purchased Becton securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

More:  BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

https://www.businesswire.com/news/home/20200228005549/en/” data-reactid=”18″>View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005549/en/

www.howardsmithlaw.com” data-reactid=”20″>Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com


More from: | Category: Medical Device Company News